> CGI's genomic signature, developed in a research collaboration with Memorial Sloan-Kettering, predicts metastasis for clear-cell renal cell carcinoma (ccRCC)
> Clear cell renal cell carcinoma is the most common form of kidney cancer with nearly 43,000 new cases in the US each year and 200,000 globally per year
RUTHERFORD, N.J., Feb. 24, 2015 (GLOBE NEWSWIRE) -- Cancer Genetics Inc (Nasdaq:CGIX) ("CGI" or "the company"), an emerging leader in DNA-based cancer diagnostics, announced today that it has identified genomic signatures that can differentiate those patients with clear cell renal carcinoma (ccRCC) whose disease is likely to relapse or metastasize. The signatures were identified in a collaborative study with Memorial Sloan-Kettering Cancer Center (MSKCC) which analyzed and genomically assessed specimens from 144 patients with both primary and metastatic lesions. Genomic signatures identified in this study have the potential to allow for better risk stratification and guided treatment selection for patients with metastatic ccRCC. CGI plans on integrating signatures identified in this study into an NGS-based panel for kidney cancer, which the company expects to be CLIA-certified and available for use for both clinical trials and clinical diagnosis and management of patients.
Clear cell renal cell carcinoma (ccRCC) is the most common subtype of kidney cancer, with approximately 43,000 new cases diagnosed in the US each year. Approximately 20-30% of ccRCC patients relapse within three years after nephrectomy. Identifying patients whose disease is likely to relapse or metastasize is essential for planning appropriate treatment strategies and improving outcome. Copy number variations in samples from patients whose disease had metastasized to the lung or bone (the two most common sites for metastasis of ccRCC) were also identified and validated in an independent dataset. For patients with early-stage disease, accurate prediction of metastatic activity will enable the delivery of personalized precision medicine with the goal of improving outcomes.
Results of the study will be presented at the Genitourinary Cancers Symposium of the American Society of Clinical Oncology (GU-ASCO). The poster presentation, titled "Association of genome-wide copy number alterations with metastasis of clear cell renal cell carcinoma" will be delivered by Banumathy Gowrishankar, Ph.D., principal clinical scientist at Cancer Genetics, on February 28 at 7:00am Eastern Time at the Rosen Shingle Creek in Orlando, Florida.
About the Genitourinary Cancers Symposium
The Genitourinary Cancers Symposium is a specialized oncology event designed for the exchange of the latest strategies in prevention, screening, diagnosis, and treatment of prostate, renal, testicular, and urothelial cancers. The symposium is cosponsored by the American Society for Clinical Oncology (ASCO), American Society for Therapeutic and Radiation Oncology (ASTRO) and the Society for Urologic Oncology (SUO).
About Cancer Genetics
Cancer Genetics, Inc. is an emerging leader in DNA-based cancer diagnostics, servicing some of the most prestigious medical institutions in the world. Our tests target cancers that are difficult to diagnose and predict treatment outcomes. These cancers include hematological, urogenital and HPV-associated cancers. We also offer a comprehensive range of non-proprietary oncology-focused tests and laboratory services that provide critical genomic information to healthcare professionals, as well as biopharma and biotech companies. Our state-of-the-art reference labs are focused entirely on maintaining clinical excellence and are both CLIA certified and CAP accredited and have licensure from several states including New York State. We have established strong research collaborations with major cancer centers such as Memorial Sloan-Kettering, The Cleveland Clinic, Mayo Clinic, Columbia University and the National Cancer Institute.
For more information, please visit or follow us:
Internet: http://www.cancergenetics.com
Twitter: @Cancer_Genetics
Facebook: www.facebook.com/CancerGenetics
Forward Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development and potential opportunities for Cancer Genetics, Inc. products and services, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to, statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, risks of cancellation of customer contracts or discontinuance of trials, risks that the transaction will not close or, if it closes, will not realize the currently anticipated benefits, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, maintenance of intellectual property rights and other risks discussed in the Company's Form 10-K for the year ended December 31, 2013 and 10-Q for the quarter ended September 30, 2014 along with other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics disclaims any obligation to update these forward-looking statements.